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ABSTRACT 
The adaptive seamless phase II/III design combines the conventional separate phases II and III 
trials into a single trial, and it allows for adaptations (e.g. sample size reassessment and early 
stopping for futility or success) after the interim analysis. In this study, we propose a simulation-
based method to determine the optimal sample size for the adaptive seamless phase II/III design. 
We assume that a power law relationship exists between the overall sample size and statistical 
power of the final test. The optimal sample size is defined as the minimum sample size that 
provides adequate power with overall type I error rate under control. To find the optimal size, we 
also take correlations between the early and the final outcomes into consideration. The 
methodology is applied to determining sample sizes in a study for a candidate treatment that can 
avoid renal damage during cardiac operations while the most effective dose of the treatment will 
be selected at the interim analysis. 
 
PUBLIC HEALTH SIGNIFICANCE 
Adaptive seamless phase II/III design eliminates the time between the traditional separate trials 
and better utilizes the data collected before the interim analysis, thus will result in faster clinical 
trials. Treatment effect can be confirmed at the final test if adequate power is achieved and the 
overall type I error rate is under control. Using these faster clinical trials, effective treatment can 
OPTIMAL SAMPLE SIZE DETERMINATION IN ADAPTIVE SEAMLESS PHASE 
II/III DESIGN 
Zhongying Xu, M.S. 
University of Pittsburgh, 2016
 
 v 
be approved sooner to benefit more patients. In addition, in an adaptive seamless phase II/III 
design more patients will be allocated to the more effective treatment than they would in 
conventional clinical trials.  
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1.0  INTRODUCTION 
Traditional clinical trials are performed in several independent phases. Phase I is the first trial 
conducted among humans and the goal is to evaluate the safety of the treatment. In phase II 
usually less than 100 patients are involved and the goal is to select appropriate dose(s) of the 
study treatment and further assess the safety. In phase III, hundreds to thousands of patients can 
be included and the goal is to confirm the safety and effectiveness of the treatments. However, 
there are several issues violating statistical principles in conventional separated trials. Thall 
(2008) mentioned that in a conventional phase II trial, the comparison between the treatment and 
standard therapy was based on the observed data from a single-arm trial and a fixed estimator 
directly obtained from the historical data. The variance of the test statistics was underestimated 
since the variability of the estimator from historical data was ignored. He also pointed out that 
bias could be caused by patient heterogeneity, because patient covariates can make even larger 
combined effects than treatment in many clinical settings. In addition, phase II trial usually has 
small sample size with limited reliability and validity. 
To improve the scientific reliability and efficiency of conventional phase II and phase III 
trials, adaptive seamless phase II/III design (ASD) was proposed, and it has become popular in 
the pharmaceutical industry (Chow and Chang, 2008). An ASD combines the conventional 
separate phases II and III trials into a single trial, and allows adaptations (e.g. sample size 
reassessment, and early stopping for futility or success) after the interim analysis at midterm 
 2 
(Figure 1). Ellenberg and Eisenberger (1985) presented a similar concept as the two-stage phase 
II/III design but restricted their method to binary outcome for a single treatment versus placebo. 
Thall et al. (1988a) gave a formal and complete presentation of an ASD, while they considered 
the same outcomes in both stages. In the setting of evaluating several experimental treatments 
versus control group, Thall et al. (1988b) proposed a modified two-stage phase II/III design with 
treatment selection in stage 1 and two-arm comparison in stage 2. When final outcome is not 
available for all patients, early outcome is used for treatment selection at the interim analysis. 
Stallard (2010) and Friede et al. (2011) take the correlation of early and late outcomes into 
consideration in the analysis of stage 2, the confirmatory stage. 
An ASD is more efficient since it eliminates the time between the trials conducted 
separately (“seamless”). Therefore, an ASD better utilizes the data before the interim analysis, 
and increases the total follow-up time for patients (Maca et al., 2006). The final analysis is 
conducted by using the data from patients enrolled before and after the midterm adaptation, so 
the total available sample sizes increases. Thus, it provides more reliable inferences than the 
traditional design. 
We need to consider whether an ASD is the proper design to the study, for efficiency and 
ethical issues. Firstly, a study with relatively shorter length of time for decision making than 
recruitment speed is desirable for an ASD. Otherwise, it losses efficiency since we have to pause 
the enrollment during the study. Secondly, pivotal studies are required to provide adequate 
information about the treatment. Separate phase II trial will be recommended if too many 
unknown information on the treatment. Moreover, the surrogate marker for treatment selection 
and study endpoints must be validated and accepted (Gaydos et al., 2009). 
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A number of authors proposed statistical approaches to an ASD, while controlling the 
overall type I error rate at a prespecified level. Group-sequential method, adaptive Dunnett 
method, and combination test method are the three main approaches (Stallard & Todd, 2011). 
The null hypothesis for these methods is that the effectiveness of the study treatments is the same 
as that of the placebo. Stallard and Todd (2003) proposed a group-sequential method based on a 
cumulative normally distributed test statistics. Under this method, only one treatment could be 
selected to continue into the subsequent stage (stage 2). Koenig et al. (2008) proposed an 
adaptive Dunnett test based on a conditional error function. Other adaptations could be made in 
the subsequent stage after an interim analysis. Bauer and Kieser (1999) proposed a combination 
test method, where the final decision for rejection was made by a combination of stage 1 and 
stage 2 P values. Comparing with the group-sequential method, both the adaptive Dunnett 
method and the combination test method allow the selection of more than one treatment at the 
interim and other adaptations. 
Based on the combination test method proposed by Bauer and Kieser, Posch et al. (2005) 
gave a general formulation of the adaptive testing procedure in the context of treatment selection. 
Friede et al. (2011) considered another setting when only information from stage 1 (early 
outcome) was available in the interim analysis for treatment selection, and confirmatory testing 
was exclusively based on the final outcomes. 
A few methods have been developed to estimate the optimal sample size for an ASD 
while controlling the prespecified overall type I error rate and achieving adequate power of the 
overall test. Bischoff and Miller (2009) suggested that sample size reassessment for the stage 2 
could be derived based on the estimated variance of outcome from the interim analysis. Fisher 
(1998) proposed a sample size estimation based on conditional power when no early stopping 
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was planned. On the other hand, Cui et al. (1999) gave an unconditional sample size calculation, 
and the new sample size was based on the assumed effect size and the estimated effect size from 
the observed data in the previous stage. However, this method might provide biased conditional 
power (Gao et al., 2008). 
A recent trial of oral propranolol treatments on complicated infantile hemangiomas was 
conducted using the ASD (Léauté-Labrèze et al., 2015). The interim analysis of the study was 
performed after the first 188 patients completed 24 weeks. The best propranolol regimen 
(3mg/kg/day for 6 months) was then selected based on the early outcome (Léauté-Labrèze et al., 
2015). In the final analysis, the effect of the selected treatment was confirmed using Posch’s 
method. In this proposal, our aim was to conduct a simulation study to examine the overall Type 
I error rate and power of the final test based on the information given in the protocol of this 
study. Our simulation was based on the work of Posch et al. (2005) and Friede et al. (2011). 
Details of the method will be described in Section 2. After proposal and before graduation, we 
plan to develop a simulation-based empirical method to estimate the optimal sample size of an 
ASD and apply it to estimate the sample size for the remote ischemic conditioning to avoid renal 
damage during cardiac operations (RICARDO) study led by Dr. John Kellum in the Department 
of Critical Care Medicine. The optimal sample size determinations for an ASD under various 
scenarios will be given in Section 3. In Section 4, we will present our simulation work for the 
study of oral propranolol treatments on complicated infantile hemangiomas (Léauté-Labrèze et 
al., 2015). In Section 5, we will describe the future work of sample size determination for the 
RICARDO study. A final concluding remark will be given in Section 6. 
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Figure 1. Comparison of traditional clinical trials and ASD. 
Adapted from “Adaptive design clinical trials: Methodology, challenges and prospect,” by R. Mahajan and K. 
Gupta, 2010, Indian journal of pharmacology, 42(4), 201. Copyright [2010] by Indian Journal of Pharmacology. 
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2.0  ADAPTIVE TREATMENT SELECTION BASED ON COMBINATION TESTS 
An ASD usually contains two stages of traditional clinical trials, a learning stage (phase IIb) and 
a confirmatory stage (phase III). In phase IIb researchers evaluate efficacy and safety among 
several candidate treatments. In an ASD, researchers will select one or two treatments based on 
the interim analysis at the end of learning stage, and then those patients in the selected treatment 
groups along with those in the control group will continue into the second stage to confirm the 
estimation of treatment effects in the first stage. 
To investigate the effectiveness of study treatment, we define the hypotheses for 
comparing the treatment success rate 𝜃𝜃𝑖𝑖, 𝑖𝑖 ∈ Ω1 = {1, … ,𝑘𝑘} to the placebo success rate 𝜃𝜃0be  
𝐻𝐻𝑖𝑖:𝜃𝜃𝑖𝑖 − 𝜃𝜃0 ≤ 0       against      𝐻𝐻𝑖𝑖′:𝜃𝜃𝑖𝑖 − 𝜃𝜃0 > 0, 𝑖𝑖 ∈ Ω1. 
To reject the elementary null hypothesis 𝐻𝐻𝑖𝑖, 𝑖𝑖 ∈  Ω1, at overall type I error rate 𝛼𝛼, for all 
subsets 𝒮𝒮 ⊆ Ω1 that contain 𝑖𝑖, the intersection hypotheses 𝐻𝐻𝒮𝒮  have to be rejected at level 𝛼𝛼, this 
is known as the closed testing principle (Marcus et al., 1976). For instance, there are three 
treatments A, B, and C, in order to reject the elementary null hypothesis 𝐻𝐻𝐴𝐴 for treatment A at 
level 𝛼𝛼, we need to reject all intersection hypotheses containing treatment A at level 𝛼𝛼, here the 
intersection hypotheses are 𝐻𝐻𝐴𝐴, 𝐻𝐻𝐴𝐴 ∩ 𝐻𝐻𝐵𝐵, 𝐻𝐻𝐴𝐴 ∩ 𝐻𝐻𝐶𝐶, and 𝐻𝐻𝐴𝐴 ∩ 𝐻𝐻𝐵𝐵 ∩ 𝐻𝐻𝐶𝐶. 
To demonstrate Posch’s method of adaptive treatment selection, we first assume the 
outcome is binary data (e.g. success and failure) sampled from Bernoulli (𝜃𝜃𝑖𝑖) for 𝑘𝑘 experimental 
treatments 𝑇𝑇1, … ,𝑇𝑇𝑘𝑘 as well as a control group 𝑇𝑇𝑜𝑜 at stage 1, each arm has 𝑛𝑛1 observations. At 
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stage 2, we also assume binary outcome for the selected treatment 𝑇𝑇𝑖𝑖, 𝑖𝑖 ∈ Ω1, and the control 
group 𝑇𝑇𝑜𝑜, with each arm including 𝑛𝑛2 observations. Assuming balanced sample size, the overall 
sample size for each group is 𝑛𝑛 = 𝑛𝑛1 + 𝑛𝑛2. 
We denote 𝑟𝑟𝑗𝑗,𝑖𝑖 the observed success rate of the 𝑖𝑖𝑡𝑡ℎ treatment at the 𝑗𝑗𝑡𝑡ℎ stage, 𝑟𝑟𝑗𝑗,0 the 
observed success rate for placebo. The standardized test statistic 𝑍𝑍𝑗𝑗,𝑖𝑖 under null for treatment 𝑖𝑖 ∈
Ω1, at stage 𝑗𝑗 = 1, 2 following normal distribution, and 𝑍𝑍𝑗𝑗,𝑖𝑖 is given by 
𝑍𝑍𝑗𝑗,𝑖𝑖 = �𝑛𝑛𝑗𝑗 �𝑟𝑟𝑗𝑗,𝑖𝑖 − 𝑟𝑟𝑗𝑗,0� 
�2𝑟𝑟�𝑗𝑗,𝑖𝑖 �1 − 𝑟𝑟�𝑗𝑗,𝑖𝑖�  ,   where ?̅?𝑟𝑗𝑗,𝑖𝑖 = (𝑟𝑟𝑗𝑗,𝑖𝑖 + 𝑟𝑟𝑗𝑗,0)/2 . 
Let 𝑝𝑝𝑖𝑖 = 1 −Φ(𝑍𝑍1,𝑖𝑖) and 𝑞𝑞𝑖𝑖 = 1 −Φ�𝑍𝑍2,𝑖𝑖� as p value for stage 1 and stage 2 
respectively, where Φ(. ) is the CDF of standard normal distribution. Next, we use Simes’s 
method to get p values for intersection hypotheses 𝐻𝐻𝒮𝒮.  
𝑝𝑝𝒮𝒮 = min
𝑖𝑖∈𝒮𝒮
𝑠𝑠
𝑙𝑙
?⃗?𝑝𝑖𝑖 , 
where 𝑙𝑙 is the rank of 𝑝𝑝𝑖𝑖 in the vector ?⃗?𝑝,  and ?⃗?𝑝 includes the 𝑝𝑝 values of all 𝑠𝑠 elementary 
hypotheses 𝐻𝐻𝑖𝑖′s in the intersection hypothesis 𝐻𝐻𝒮𝒮, 𝑖𝑖 ∈ 𝒮𝒮.  
We denote 𝑝𝑝𝒮𝒮 as the stage 1 p value for intersection hypotheses 𝐻𝐻𝒮𝒮 and 𝑞𝑞𝒮𝒮 as the stage 2 
p value for intersection hypotheses 𝐻𝐻𝒮𝒮 obtained from the Simes test. For simplicity, we assume 
only one treatment is selected to continue into stage 2. We define 𝑞𝑞𝒮𝒮 = 𝑞𝑞𝒮𝒮∩Ω2 where Ω2 ⊆ Ω1 is 
the treatment selected for the second stage and 𝑞𝑞∅ = 1, 𝑞𝑞𝒮𝒮 will be equal to the p value for the 
selected treatment in stage 2.  
To combine the p values from the two stages, we use the weighted inverse normal 
method to define a combination p values through the function: 
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𝐶𝐶(𝑝𝑝𝑖𝑖, 𝑞𝑞𝑖𝑖) = 1 −Φ[𝜐𝜐Φ−1(1 − 𝑝𝑝𝑖𝑖) + 𝜔𝜔Φ−1(1 − 𝑞𝑞𝑖𝑖)] , 
where 𝜐𝜐 = �𝑛𝑛1 𝑛𝑛⁄ ,𝜔𝜔 = �𝑛𝑛2 𝑛𝑛⁄   such that 𝜐𝜐2 + 𝜔𝜔2 = 1.  
We define the decision function of a combination test  
𝜑𝜑𝐶𝐶(𝑝𝑝𝑖𝑖,𝑞𝑞𝑖𝑖) = � 1       𝑖𝑖𝑖𝑖 𝑝𝑝𝑖𝑖 ≤ 𝑎𝑎 𝑜𝑜𝑟𝑟 𝑏𝑏𝑜𝑜𝑏𝑏ℎ 𝑝𝑝𝑖𝑖 ≤ 𝑏𝑏 𝑎𝑎𝑛𝑛𝑎𝑎 𝐶𝐶(𝑝𝑝𝑖𝑖, 𝑞𝑞𝑖𝑖) ≤ 𝑐𝑐0             𝑜𝑜𝑏𝑏ℎ𝑒𝑒𝑟𝑟𝑒𝑒𝑖𝑖𝑠𝑠𝑒𝑒                                                      
Therefore, we can make a decision, reject the null for 𝜑𝜑𝐶𝐶 = 1, or not. Treatment will be 
stopped because of early rejection of the null hypothesis (𝑝𝑝𝑖𝑖 ≤ 𝑎𝑎), or futility (𝑝𝑝𝑖𝑖 > 𝑏𝑏). With 
prespecified a and b, c can be solved by  
𝑎𝑎 + ∫ ∫ 1[𝐶𝐶(𝑥𝑥,𝑦𝑦)≤𝑐𝑐]10𝑏𝑏𝑎𝑎 𝑎𝑎𝑑𝑑𝑎𝑎𝑑𝑑 = 𝛼𝛼 , 
where we define the indicator function 
1[.]  = � 1       𝑖𝑖𝑖𝑖 𝐶𝐶(𝑑𝑑,𝑑𝑑) ≤ 𝑐𝑐0       𝑜𝑜𝑏𝑏ℎ𝑒𝑒𝑟𝑟𝑒𝑒𝑖𝑖𝑠𝑠𝑒𝑒        
In the final analysis, the null hypothesis 𝐻𝐻𝑖𝑖, 𝑖𝑖 ∈  Ω1, will be rejected at familywise type I 
error rate 𝛼𝛼, if for each 𝒮𝒮 ⊆ Ω1, the intersection hypothesis 𝐻𝐻𝒮𝒮 is rejected at level 𝛼𝛼, i.e. 
𝜑𝜑𝐶𝐶(𝑝𝑝𝒮𝒮 , 𝑞𝑞𝒮𝒮) = 1.  
Friede et al. (2011) further extended the above method and took the correlation between 
early and final outcome into consideration. Generally, combination test with closed testing 
principle becomes more conservative when the correlation between early and final outcome 
decreases (Friede et al., 2011). Since early and final outcomes are usually different but correlated 
in many real applications, our simulation was based on the work of Posch et al. (2005) and 
Friede et al. (2011). 
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3.0  OPTIMAL SAMPLE SIZE DETERMINATION 
Our objective is to determine the optimal sample size for an ASD through simulation using a 
prespecified type I error rate and power. The total sample size includes estimated sample size 𝑛𝑛1 
for stage 1 in each arm and reassessed sample size 𝑛𝑛2 for stage 2 in each arm based on the 
interim analysis. We assume a “power law relationship” exists between the overall sample size 
and statistical power of the final test. A power law is a functional relationship between the two 
quantities, where one quantity varies as a power of another. That is,  
𝑃𝑃(𝑁𝑁) = 1 + 𝜋𝜋𝑁𝑁−𝛾𝛾, 
where 𝑁𝑁 is the total sample size, 𝑃𝑃(𝑁𝑁) is the statistical power, 𝜋𝜋 < 0 and 𝛾𝛾 > 0 need to be 
estimated. In this study, we consider three different scenarios as described in detail below. 
Paragraph. 
3.1 SCENARIO I: ESTIMATE THE OPTIMAL SAMPLE SIZE 𝑵𝑵𝑵𝑵 FOR STAGE 1 
WITH FIXED FUNCTIONAL RELATIONSHIP BETWEEN 𝑵𝑵𝑵𝑵 AND 𝑵𝑵𝑵𝑵. 
Let 𝑁𝑁1 be the total sample size at stage 1, 𝑃𝑃(𝑁𝑁1) be the power of the final test which is a function 
of 𝑛𝑛1, and 𝐴𝐴(𝑁𝑁1) be the overall type I error rate which is a function of 𝑛𝑛1. We assume that i) the 
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ratio of sample size in treatment vs. placebo is fixed; ii) the functional relationship between 𝑁𝑁 
and 𝑁𝑁2, 𝑁𝑁2 = 𝑖𝑖(𝑁𝑁1), is fixed. Therefore, we can estimate the optimal total sample size 𝑁𝑁 by 
𝑁𝑁1 𝑜𝑜𝑜𝑜𝑡𝑡𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙 = 𝑚𝑚𝑖𝑖𝑛𝑛{𝑁𝑁1:𝑃𝑃(𝑁𝑁1) > 𝑃𝑃∗,𝐴𝐴(𝑁𝑁1) ≤ 𝛼𝛼∗} , 
𝑁𝑁𝑜𝑜𝑜𝑜𝑡𝑡𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙 = 𝑁𝑁1 𝑜𝑜𝑜𝑜𝑡𝑡𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙 + 𝑖𝑖�𝑁𝑁1 𝑜𝑜𝑜𝑜𝑡𝑡𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙� , 
where 𝛼𝛼∗ is a prespecified overall type I error rate, and we plan to achieve at least 𝑃𝑃∗ power. 
For our future work, the RICARDO study fits this scenario. We need to assume a 
prespecified functional relationship between 𝑛𝑛1 and 𝑛𝑛2, and conduct simulations to determine the 
optimal value of 𝑛𝑛1 and achieve adequate power with type I error rate under controlled.  
3.2 SCENARIO II: ESTIMATE THE OPTIMAL SAMPLE SIZE 𝑵𝑵𝑵𝑵 FOR STAGE 2 
WITH FIXED SAMPLE SIZE 𝑵𝑵𝑵𝑵 FOR STAGE 1. 
With a fixed sample size 𝑁𝑁1 for stage 1, we aim to estimate the minimum sample size 𝑁𝑁2 for 
stage 2 in order to achieve the greatest power of the final test under a prespecified overall type I 
error rate. In other words, we are looking for the best adaptation method, i.e. we will choose the 
best function 𝑔𝑔(. ) to achieve the greatest power with minimum sample size, 𝑁𝑁2 = 𝑔𝑔(𝑁𝑁1)  and 
𝑁𝑁𝑜𝑜𝑜𝑜𝑡𝑡𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙 = 𝑁𝑁1 + 𝑔𝑔(𝑁𝑁1). 
Sample size estimation in the protocol of Léauté-Labrèze et al. (2015) was performed 
under this scenario. They fixed stage 1 sample size per arm to be 35, then explored the power 
change as a function of 𝑁𝑁2 with the one-sided overall type I error rate α = 0.005.  
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3.3 SCENARIO III: ESTIMATE THE SET OF OPTIMAL SAMPLE SIZES {𝑵𝑵𝑵𝑵,𝑵𝑵𝑵𝑵} 
WHERE 𝑵𝑵𝑵𝑵 AND 𝑵𝑵𝑵𝑵 ARE INDEPENDENT. 
In this scenario, we assume that 𝑁𝑁1 and 𝑁𝑁2 are independent, thus no sample size adaptation 
method exists. We will find the set of optimal sample sizes {𝑁𝑁1,𝑁𝑁2} when the greatest power is 
reached and the type I error rate is controlled. The power could be shown in a 3D space, where 
changing either 𝑁𝑁1 or 𝑁𝑁2 changes the power. 
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4.0  SIMULATION-BASED TYPE I ERROR RATE AND POWER 
In the protocol of oral propranolol treatments on complicated infantile hemangiomas study 
(Léauté-Labrèze et al., 2015), four treatment regimens with a control group were considered. 
Only one treatment was selected and continued along with placebo in stage 2. They denoted 𝑛𝑛1 
as stage 1 sample size for each arm, 𝑛𝑛2 as stage 2 sample size for each arm. Therefore, the 
minimum total sample size was 5𝑛𝑛1 + 2𝑛𝑛2. From the interim analysis, the estimated success rates 
were: 10% for placebo, 30% for regimen 1 (1 mg/kg/day for 3 months), 35% for regimen 2 (1 
mg/kg/day for 6 months), 40% for regimen 3 (3 mg/kg/day for 3 months), and 50% for regimen 
4 (3 mg/kg/day for 6 months). The overall one-sided type I error rate was 𝛼𝛼 = 0.005 and power > 
90% was considered adequate.  
Using the method proposed by Posch et al. (2005), we simulated the type I error rates and 
powers under different sets of sample sizes and only the most effective regimen was chosen after 
the interim analysis. As shown in Tables 1 and 2, we got similar results as those shown in the 
protocol. We used the R package ASD (Parsons et al., 2012) to produce these results. 
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Table 1. Estimated one-sided type I error rate when the most effective regimen is chosen at the 
interim analysis with various (n1, n2). 
Level (superiority) of Type I Error Rate Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.0047 0.0010 0.0013 0.0012 0.0012 35 40 255 
0.0046 0.0010 0.0013 0.0011 0.0012 35 45 265 
0.0046 0.0010 0.0013 0.0011 0.0012 35 50 275 
0.0047 0.0010 0.0012 0.0014 0.0011 35 55 285 
0.0047 0.0009 0.0012 0.0015 0.0011 35 60 295 
Note. Results were given based on 104 simulations for each scenario. 
 
Table 2. Estimated power when the most effective regimen is chosen at the interim analysis with 
various (n1, n2). 
Power (superiority) Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.9431 0.0022 0.0108 0.0449 0.8852 35 40 255 
0.9501 0.0022 0.0111 0.0462 0.8906 35 45 265 
0.9544 0.0023 0.0115 0.0472 0.8934 35 50 275 
0.9576 0.0023 0.0117 0.0480 0.8956 35 55 285 
0.9610 0.0023 0.0120 0.0494 0.8973 35 60 295 
Note. Results were given based on 104 simulations for each scenario. 
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5.0  RICARDO STUDY 
Researches have found that remote ischemic preconditioning (RIPC), having transient external 
compression of the upper arm, prior to cardiac surgery is associated with reducing the occurrence 
of acute kidney injury (AKI) and is strongly associated with the release of cell-cycle arrest 
biomarkers into the urine (Zarbock, et al., 2015a; Kashani, et al., 2013; Bihorac, et al., 2009). 
John Kellum, MD proposed a multicenter, randomized, double-blind, adaptive seamless phase 
II/III trial entitled “Remote ischemic conditioning to avoid renal damage during cardiac 
operations (RICARDO)” to further investigate the effectiveness of this intervention, including an 
assessment of the effect size and the selection of optimal dose of RIPC.  
By using the adaptive seamless phase II/III design, four regimens with different doses of 
RIPC were used along with the control group (sham-RIPC intervention) at stage 1. In the interim 
analysis, we will select the regimen that yields the highest proportion of urinary [TIMP-
2]•[IGFBP7] ≥ 0.5 (ng/ml)2/1000 and without a major adverse event (including any increase in 
AKI). The selected regimen and the control group will be used in stage 2 to determine the overall 
effectiveness. The primary endpoint is the major adverse kidney events at 90-days post surgery 
(MAKE90), including death and dialysis or persistent renal dysfunction (2x baseline creatinine). 
In order to determining the optimal sample size, we take into account the correlation between the 
early outcome (proportion of biomarker [TIMP-2]•[IGFBP7] ≥ 0.5 (ng/ml)2/1000) and the final 
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outcome (MAKE90). In addition, we utilized closed testing procedure together with combination 
tests to control the family-wise one-sided type I error rate to 𝛼𝛼 = 0.005. 
In the pilot study conducted by Zarbock, et al.(2015b), patients were randomized into the 
intervention group and the control group. Patients in the intervention group were treated with 3 
cycles of 5-min inflation of a blood-pressure cuff to 200 mm Hg (or at least to a pressure 50 
mmHg higher than the systolic arterial pressure) on one upper arm; each inflation is followed by 
a 5-min reperfusion with the cuff deflated. This intervention is considered as regimen 2 in the 
RICADO study. Patients in the control group are treated with 3 cycles of upper limb ‘pseudo’-
ischemia at a lower pressure; in each cycle a 5-min blood-pressure cuff inflation to a pressure of 
20 mm Hg higher than the systolic arterial pressure is followed by a 5-min cuff deflation. In the 
RICARDO study, regimen 1 has a lower dose (2 cycles for 3 minutes) than regimen 2 dose; 
regimen 3 and regimen 4 have higher doses with 3 cycles of 7 minutes and 4 cycles of 5 minutes, 
respectively. 
We estimated the proportion of MAKE90 for sham-RIPC (𝜃𝜃�0= 0.25) and regimen 2 (𝜃𝜃�2= 
0.14) from the previous study (Zarbock, et al., 2015b). We further assumed the proportion of 
MAKE90 for regimen 1, 3, and 4 as 𝜃𝜃�1 = 0.2, 𝜃𝜃�3 = 0.12, and 𝜃𝜃�4 = 0.10, respectively. The early 
outcome is defined as the proportion of urinary [TIMP-2]•[IGFBP7] ≥ 0.5 (ng/ml)2/1000 for 
each regimen and for the control. From the pilot data, we estimated this proportion as ?̂?𝑝0 = 0.25 
for sham-RIPC and ?̂?𝑝2 = 0.37 for regimen 2. For regimen 1, 3, and 4, we assumed the proportion 
as ?̂?𝑝1 = 0.31, ?̂?𝑝3 = 0.39, and ?̂?𝑝4 = 0.41 respectively. Moreover, we estimated the correlation 
between early outcome and MAKE90 from the pilot data, and it is denoted by phi coefficient, 𝜙𝜙� = 
-0.15. We plan for having equal sample size per arm, and we expected the overall power to be at 
least 80%. 
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Sample size estimation for the RICARDO study is performed under scenario I as 
mentioned in Section 3. We do not have enough information about the required sample size for 
stage 1, so we explored different values of  𝑛𝑛1 in our simulations. Moreover, we controlled the 
ratio of stage 2 sample size (𝑛𝑛2) to stage 1 sample size (𝑛𝑛1) in between 5 and 20. For each value 
of 𝑛𝑛1, we estimated the total sample size with four different ratios of 𝑛𝑛2 to 𝑛𝑛1. The results are 
shown in Tables 3 to 8. 
Table 3. Estimated one-sided type I error rate when the most effective regimen is chosen at the 
interim analysis with n1 = 15 and different n2. 
Level (superiority) of Type I Error Rate Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.0038 0.0004 0.0009 0.0016 0.0009 15 150 375 
0.0040 0.0004 0.0009 0.0017 0.0010 15 200 475 
0.0040 0.0003 0.0010 0.0016 0.0011 15 250 575 
0.0042 0.0003 0.0012 0.0016 0.0011 15 300 675 
Note. Results were given based on 104 simulations for each scenario. 
 
Table 4. Estimated power when the most effective regimen is chosen at the interim analysis with n1 = 
15 and different n2. 
Power (superiority) Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.5565 0.0058 0.0973 0.1775 0.2759 15 150 375 
0.6865 0.0071 0.1335 0.2258 0.3201 15 200 475 
0.7709 0.0094 0.1618 0.2584 0.3413 15 250 575 
0.8217 0.0109 0.1830 0.2781 0.3497 15 300 675 
Note. Results were given based on 104 simulations for each scenario. 
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Table 5. Estimated one-sided type I error rate when the most effective regimen is chosen at the 
interim analysis with n1 = 20 and different n2. 
Level (superiority) of Type I Error Rate Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.0040 0.0004 0.0009 0.0018 0.0009 20 150 400 
0.0038 0.0004 0.0009 0.0016 0.0009 20 200 500 
0.0039 0.0004 0.0009 0.0017 0.0009 20 250 600 
0.0040 0.0004 0.0010 0.0015 0.0011 20 300 700 
Note. Results were given based on 104 simulations for each scenario. 
 
Table 6. Estimated power when the most effective regimen is chosen at the interim analysis with n1 = 
20 and different n2. 
Power (superiority) Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.5779 0.0047 0.0977 0.1834 0.2921 20 150 400 
0.7054 0.0058 0.1316 0.2303 0.3377 20 200 500 
0.7869 0.0079 0.1588 0.2624 0.3578 20 250 600 
0.8376 0.0091 0.1802 0.2812 0.3671 20 300 700 
Note. Results were given based on 104 simulations for each scenario. 
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Table 7. Estimated one-sided type I error rate when the most effective regimen is chosen at the 
interim analysis with n1 = 30 and different n2. 
Level (superiority) of Type I Error Rate Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.0038 0.0003 0.0009 0.0018 0.0008 30 150 450 
0.0040 0.0004 0.0009 0.0018 0.0009 30 200 550 
0.0039 0.0004 0.0009 0.0017 0.0009 30 250 650 
0.0038 0.0004 0.0009 0.0016 0.0009 30 300 750 
Note. Results were given based on 104 simulations for each scenario. 
Table 8. Estimated power when the most effective regimen is chosen at the interim analysis with n1 = 
30 and different n2. 
Power (superiority) Sample Size 
Overall Regimen 1 Regimen 2 Regimen 3 Regimen 4 n1 n2 min(N) 
0.6152 0.0036 0.0969 0.1943 0.3204 30 150 450 
0.7364 0.0048 0.1278 0.2394 0.3644 30 200 550 
0.8154 0.0068 0.1550 0.2695 0.3841 30 250 650 
0.8633 0.0079 0.1749 0.2875 0.3930 30 300 750 
Note. Results were given based on 104 simulations for each scenario. 
From Tables 3-8, the overall type I error rate was controlled under 0.005 for all settings. 
We found that statistical power increases as total sample size gets larger. The power of the final 
test achieves 80% when total sample size is closed to 650. Based on these results, we suggest the 
acceptable sample size to be 675 patients in total, with recruiting 15 patients per arm in stage 1 
and 300 patients per arm in stage 2. 
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Moreover, we compared the required stage 1 sample size using an ASD with the required 
sample size using other four traditional phase II trial designs: the two-arm trial design, the group-
sequential design, and the multi-arm trial designs with and without treatment selection. We used 
the early outcome (the proportion of urinary [TIMP-2]•[IGFBP7] ≥ 0.5 (ng/ml)2/1000) as the 
endpoint for hypothesis testing in the four traditional designs. The same settings as those in the 
RICARDO study were used, which include four candidate treatment regimens and a control 
group. Sample size estimations were done using the R package ASD and the R packages MAMS 
(Magirr et al., 2012). The results of the estimated sample sizes using different trial designs are 
summarized in Table 9. If we conduct four separate two-armed trials, the required total sample 
size is 88; if we conduct four separate group-sequential trials, the maximum required sample size 
is 112; if we use a multi-arm study, 90 and 75 patients with and without treatment selection, 
respectively, will be required for the design. As shown in Tables 3-8, we only need 75 patients 
for stage 1 if using an ASD. These results showed that an ASD can reduce sample size for stage 
1 and allocate more patents to more effective treatment in stage 2.  
 
Table 9. Comparison of maximum sample size required for different designs. 
Design Option  Maximum Sample Size 
  Four separate two-armed trials 88 
  Four separate group-sequential trials 112 
  Multi-arm study with treatment selection 90 
  Multi-arm study without treatment selection 75 
  Adaptive seamless design (stage 1) 75 
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We checked the power law assumption by plotting estimated total sample size and power 
under twelve twelve different settings of 𝑛𝑛1 and 𝑛𝑛2 in Tables 3-8 and comparing their deviation 
from the theoretical curve. Figure 2 shows that the points scattered around the theoretical curve 
with relatively small departures. We concluded that a power law relationship between total 
sample size and statistical power is probable. 
 
Figure 2. Power law relationship between total sample size and statistical power. 
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6.0  DISCUSSION 
For a trial with complex setting such as an adaptive seamless design, it is more feasible to 
determine the sample size through simulations than deriving the closed form of the sample size 
formula. Posch et al. (2005) proposed an empirical method to estimate the effect of the selected 
treatment. They used the closed testing principle together with the combination tests in the final 
analysis. Friede et al. (2011) extended the method of Posch et al. and took the correlation of early 
and final outcomes into consideration. Our simulations were based on the work of both Posch et 
al. and Friede et al. and a power law relationship between the total sample size and the statistical 
power was assumed.  
Based on the information provided in the protocol of the trial of oral propranolol in 
infantile hemangioma (Léauté-Labrèze et al., 2015), we estimated the first-stage and the second-
stage sample sizes by controlling the overall type I error rate and the power of the final test, 
using the method of Posch et al. (2005). For the RICARDO study, we applied the same method 
to estimate the required total sample size via simulations. The power law relationship is a 
reasonable assumption since the statistical power is expected to converge with infinitely large 
sample size. With a prespecified functional relationship between the sample sizes in stages 1 and 
in stage 2 (5 ≤ 𝑛𝑛2 𝑛𝑛1 ≤⁄  20), we estimated the total required sample size by assuming different 
values of 𝑛𝑛1. Based on the simulation results, we suggested the total required sample size to be 
675 patients under the condition that the overall type I error rate is less than 0.005 and the overall 
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power is greater than 80%. Moreover, our simulation results showed that the required sample 
size in the RICARDO study is smaller if an ASD is used in stage 1, as compared with the sample 
size required by other traditional phase II designs.  
An ASD not only shortens the total length of time, but it also can assign more patients to 
the more effective treatment. It is worth noting that despite many strengths of an ASD, it may not 
always be the best choice. When there is a lack of information about the treatment of interest, the 
final treatment recommendation derived from a study using ASD could be misleading. In 
addition, an ASD will lose its efficiency if the recruitment rate is relatively fast with respect to 
the waiting time for the interim analysis. In the RICARDO study, we had obtained sufficient 
information about the treatment of interest from pilot studies, and the expected waiting time for 
decision making is short relative to recruitment time. Therefore, it is feasible and reasonable to 
use an adaptive seamless design in the RICARDO study.  
One of the limitations in our sample size estimation for the RICARDO study is that we 
did not simulate an intensive set of (𝑛𝑛1,𝑛𝑛2), sample sizes for stage 1 and stage 2 within a 
prespecified range of the total sample size to check the power law assumption. Currently, we 
fitted a curve with twelve points of (𝑛𝑛1,𝑛𝑛2) with a total sample size ranging from 375 to 750 
patients. Simulations with more data points of (𝑛𝑛1,𝑛𝑛2) will be needed to capture the lower part 
features and the convergence limit of the power law curve.  
Besides, a statistical study is required to assess the fit of the power law curve. We will 
need to investigate the goodness of fit of the power law relationship. An alternative way to assess 
the fit is to conduct multiple simulations and generate an interval of power estimates for each 
sample size (e.g. with the first and the third quartiles being the lower and upper ends of the 
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interval), then we can check whether the power law curve fitted by the median powers will pass 
through all intervals.  
We have tried different packages in R and different macros in SAS for sample size and 
power estimations. Among them, the R package ASD performs the best in replicability also takes 
the correlation between the early and the final outcomes into account. Our simulations showed 
that package ASD gave different estimation results for different seed numbers. To overcome the 
variability, we suggest running simulations with random choices of different seed numbers and 
reporting the median of the estimated sample sizes. 
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APPENDIX: R CODE FOR SAMPLE SIZE SIMULATION IN THE RICARDO STUDY 
### Simulate sample size in ASD  
library(asd) 
# Estimated one-sided type I error rate when the most effective regimen is chosen at the interim 
analysis  
result_type1<- treatsel.sim(n=list(stage1=15, stage2=150), 
effect=list(early=rep(0.75,5), final=rep(0.25,5)), 
               outcome=list(early="B", final="B"), nsim=10000, 
corr=0.15, seed=4358098, select=1, 
weight=NULL, level=0.005, ptest=c(1,4), 
method="invnorm", fu=FALSE, file = "") 
# Estimated power when the most effective regimen is chosen at the interim analysis 
result_p<- treatsel.sim(n=list(stage1=15, stage2=150), 
effect=list(early=c(0.75,0.69,0.63,0.61,0.59), final=c(0.25,0.2,0.14,0.12,0.10)), 
outcome=list(early="B", final="B"), nsim=10000, 
corr=0.15, seed=4358098, select=1, 
weight=NULL, level=0.005, ptest=c(1:4), 
method="invnorm", fu=FALSE, file = "") 
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### Simulate sample size in other study designs  
library(MAMS) 
delta <- 6 
sigma <- sqrt(25) 
# four separate two-arm 
mams.rev(K=1, J=1, alpha=0.025, power=0.8, r=1, r0=1, 
         p=pnorm(delta/(sqrt(2)*sigma)) , p0=0.5) 
# four separate group-seq 
mams.rev(K=1, J=2, alpha=0.025, power=0.8, r=1:2, r0=1:2, 
         p=pnorm(delta/(sqrt(2)*sigma)) , p0=0.5, 
u.shape="triangular", l.shape="triangular")
# multi-arm w/o selection 
mams(K=4, J=1, alpha=0.025, power=0.8, r=1, r0=1, 
       p=pnorm(delta/(sqrt(2)*sigma)) , p0=0.5) 
# multi-arm with treatment selection 
mams(K=4, J=2, alpha=0.025, power=0.8, r=1:2, r0=1:2, 
     p=pnorm(delta/(sqrt(2)*sigma)) , p0=0.5, 
u.shape="triangular", l.shape="triangular")
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